In 2003, Michael Clarke's group first identified a CD44+, CD24lo, ESA+ and lineage- subpopulation of human breast cancer cells, which can initiate tumors in immune-deficient NOD/SCID mice[2]. This evidence concerns the gene CD44 and breast cancer.